ClinicalTrials.gg
CompletedNCT01639014LIFEUpdated Apr 1, 2015

Effect of F2695 on Functional Recovery After Ischemic Stroke

A Phase 3 interventional study of F2695 and placebo in Ischemic Stroke, sponsored by Pierre Fabre Medicament. Completed at 87 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-01.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Ischemic Stroke with a site in Russian Federation — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Russian Federation.

Enrollment
5th of 19
532 · median 120
Started
2012
with 1 other
Phase 3
8 of 28
none open now
Registered
3rd of 28
by date

Among the 28 studies in Ischemic Stroke with a site in Russian Federation, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 3, and was the 3rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 28 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ischemic Stroke with a site in Russian Federation, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient, 18 to 80 years of age
  • Confirmed acute ischemic stroke within the past 2 - 10 days
  • Unilateral motor deficit,
  • National Institutes of Health stroke scale (NIHSS) motor score >= 5
  • Modified Rankin Scale (mRS) of 4 or 5
  • Able and willing to comply with the site rehabilitation program requirements

Exclusion criteria

Exclusion Criteria:

  • Aphasia
  • Severe post-stroke condition
  • Active depressive episode
  • Intra-cerebral hemorrhage
  • Use of anti-depressant drugs
  • Cardiac rhythm disorder
  • Uncontrolled arterial hypertension
  • Other severe acute or chronic medical or psychiatric condition.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
532 participants (actual)

Study arms

  • Experimental
    F2695

    Drug: F2695

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • DrugF2695

    75 mg OD in 2 capsules

  • Drugplacebo

    2 capsules

06

What researchers measure

Primary outcomes

  1. Percentage of patients with a Modified Rankin Scale (mRS) less than or equal to 1 at Week 12

    Time frame: week 12

Secondary outcomes

  1. Percentage of patients with NIHSS score less than or equal to 5 at Week 12

    Time frame: week 12

  2. Percentage of patients with at least one moderate to severe depressive

    Time frame: Baseline to week 12

  3. Change from baseline to Week 12 of the mean NIHSS total and motor scores

    Time frame: baseline to week 12

  4. Safety and tolerability assessed by the investigator including SAEs, AEs, vital signs, ECG,physical examination and laboratory tests

    Time frame: baseline to week 12

  5. Percentage of patients with a mRS score less than or equal to 2 at Week 12

    Time frame: baseline to week 12

07

Study locations

87 sites
  • Cliniques Universitaires Saint Luc
    Brussels, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, Belgium
  • Universitaire Ziekenhuis Gasthuisberg
    Leuven, Belgium
  • Clinique Saint-Joseph
    Liege, Belgium
  • Regional Ziekenhuis Sint-Trudo
    Sint-Truiden, Belgium
  • Sint-Andriesziekenhuis
    Tielt, Belgium
  • Academisch Ziekenhuis Sint Augustinus
    Wilrijk, Belgium
  • Fakultní nemocnice u sv. Anny v Brne
    Brno, Czech Republic
  • Fakultní nemocnice Hradec Králové
    Hradec Kralové, Czech Republic
  • Litomyšlská Nemocnice, a.s.
    Litomyšl, Czech Republic
  • Fakultní nemocnice Olomouc
    Olomouc, Czech Republic
  • Vítkovická nemocnice a.s.
    Ostrava - Vítkovice, Czech Republic
  • Fakultní Nemocnice Ostrava
    Ostrava, Czech Republic
  • Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon
    Besançon, France
  • Clinique des Cèdres
    Cornebarrieu, France
  • Centre Hospitalier de Lens
    Lens, France
  • Hôpital Roger Salengro
    Lille, France
  • Groupe Hospitalier Paris Saint Joseph
    Paris, France
  • Hopital Lariboisière
    Paris, France
  • Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie
    Poitiers, France
  • Centre Hospitalier Universitaire de Saint Etienne, Hôpital Nord
    Saint Priest en Jarez, France
  • Hôpital Purpan
    Toulouse, France
  • Neurologische Klinik GmbH
    Bad Neustadt/Saale, Germany
  • Universitätsklinik Charité, Campus Mitte
    Berlin, Germany
  • Universitätsklinikum Bonn
    Bonn, Germany
  • Universitätsklinikum Erlangen
    Erlangen, Germany
  • Universitätsklinikum Essen
    Essen, Germany
  • Freiburger Universitätsklinik
    Freiburg, Germany
  • Asklepios Klinik Altona
    Hamburg, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Germany
  • Universitätsklinikum Münster
    Münster, Germany
  • Asklepios Fachklinikum Teupitz
    Teupitz, Germany
  • Jahn Ferenc Dél-pesti Kórház
    Budapest, Hungary
  • Magyar Honvédség Honvédkórház
    Budapest, Hungary
  • Semmelweis Egyetem Neurológiai Klinika
    Budapest, Hungary
  • Debreceni Egyetem Orvos- és Egészségtudományi Centrum
    Debrecen, Hungary
  • Petz Aladár Megyei Oktató Kórház
    Gyor, Hungary
  • Kaposi Mór Megyei Oktató Kórhaz
    Kaposvár, Hungary
  • BAZ Megyei és Egyetemi Oktató Kórház
    Miskolc, Hungary
  • Kanizsai Dorottya Kórház
    Nagykanizsa, Hungary
  • Jósa András Oktató Kórház
    Nyíregyháza, Hungary
  • Soproni Erzsébet Oktató Kórház
    Sopron, Hungary
  • Fejér Megyei Szent György Kórház
    Székesfehérvár, Hungary
  • Azienda Sanitaria Ospedaliera "San Giovanni Battista"
    Foligno, Italy
  • Azienda Ospedaliera San Gerardo
    Monza, Italy
  • IRCCS "Istituto Neurologico C. Mondino"
    Pavia, Italy
  • Ospedale Santa Maria della Misericordia
    Perugia, Italy
  • IRCCS Fondazione Santa Lucia
    Roma, Italy
  • Istituto Clinico Humanitas
    Rozzano, Italy
  • Hospital Garcia de Orta
    Almada, Portugal
  • Hospitais da Universidade de Coimbra
    Coimbra, Portugal
  • Hospital de Santa Maria
    Lisboa, Portugal
  • Centro Hospitalar do Porto / Hospital Geral de Santo António
    Porto, Portugal
  • Hospital de São João
    Porto, Portugal
  • Municipal Healthcare Institution "Municipal Clinical Hospital # 3"
    Chelyabinsk, Russian Federation
  • Regional Hospital #1, Ekaterinburg
    Ekaterinburg, Russian Federation
  • Professor S.V. Ochapovsky Territorial Clinical Hospital #1
    Krasnodar, Russian Federation
  • Clinical Hospital Number 31
    Moscow, Russian Federation
  • Non-state Healthcare Institution "N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway
    Moscow, Russian Federation
  • Scientific Research Neurology Institute of Russian Academy of Medical Services
    Moscow, Russian Federation
  • State Budget Healthcare Institution "City clinical hospital #20"
    Moscow, Russian Federation
  • State Institution of Healthcare of Moscow City "City Clinical Hospital #61"
    Moscow, Russian Federation
  • State Institution "Saint Petersburg I.I. Dzhanelidze Research Institute of Emergency"
    Petersburg Saint, Russian Federation
  • Municipal Medical Institute "N.I.Pirogov City Clinical hospital #1"
    Samara, Russian Federation
  • State Healthcare Institution "Samara M.I.Kalinin Regional Clinical Hospital"
    Samara, Russian Federation
  • Smolensk State Medical Academy of RosZdrav
    Smolensk, Russian Federation
  • Bashkirian State Medical University
    Ufa, Russian Federation
  • Hospital General de Albacete
    Albacete, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Spain
  • Hospital Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitario de Girona Doctor Josep Trueta
    Gerona, Spain
  • Hospital Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario La Princesa
    Madrid, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
  • Hospital Clínico Universitario de Santiago de Compostela
    Santiago de Compostela, Spain
  • Hospital de Tortosa Verge de la Cinta
    Tortosa, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, Spain
  • Danderyds Sjukhus AB
    Danderyd, Sweden
  • Sahlgrenska Universitetsjukhuset
    Göteborg, Sweden
  • Universitetssjukhuset Linköping
    Linköping, Sweden
  • Skånes Universitetssjukhus i Lund
    Lund, Sweden
  • Mora lasarett
    Mora, Sweden
  • Kärnsjukhuset i Skövde-KSS
    Skövde, Sweden
  • Universitätsspital Basel
    Basel, Switzerland
  • Centre Hospitalier Universitaire Vaudois
    Lausanne, Switzerland
  • Klinik Hirslanden
    Zürich, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2012
First posted
Jul 12, 2012
Start
Jul 2012
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Apr 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01639014
Responsible party
Sponsor
First posted
Jul 12, 2012
Start date
Jul 2012
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Apr 1, 2015

Study contacts

François Chollet
principal investigator · Hôpital Purpan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion